Sector: Materials
Director information for APTARGROUP INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| B. CRAIG OWENS | Former CFO & CAO of The Campbell’s Company; Independent Director; Chair | 71 | ["Chief Financial Officer and Chief Administrative Officer of The Campbell\u2019s Company from 2008 to 2014", "Director of Crown Holdings, Inc.", "Former director of Dean Foods Company and J. C. Penney Company, Inc.", "Extensive experience in consumer food and beverage industries", "Significant expertise in financial reporting, accounting, corporate finance and capital markets", "Audit committee financial expert", "audit committee financial expert", "experience in financial reporting", "oversight of internal controls", "expertise in compliance and cybersecurity"] | ["Corporate Governance", "Audit (Chair)", "Management Development and Compensation", "Audit Committee"] | 2026 |
| CANDACE MATTHEWS | Board Chair, Aptar; Chair of the Board | 67 | ["Former Chief Reputation Officer for Amway Corp.", "Former Regional President of the Americas at Amway", "Former Chief Marketing Officer at Amway", "Executive positions at multinational beauty companies", "Public company director experience", "Expertise in beauty and consumer goods industry"] | ["Management Development and Compensation", "Corporate Governance"] | 2026 |
| GEORGE L. FOTIADES | Executive Chairman of Elio Health; Director | 72 | ["Chairman of the Board of Aptar from May 2018 to May 2023", "Executive Chairman of Elio Health since 2022", "Former President and CEO of Cantel Medical Corp.", "Operating Partner at Five Arrows Capital Partners", "Partner of Healthcare Investments at Diamond Castle Holdings LLC", "Chairman of Catalent Pharma Solutions, Inc.", "Director of Prologis, Inc.", "Audit committee financial expert"] | ["Audit"] | 2026 |
| G. Fotiades | ["audit committee financial expert", "experience in financial reporting", "oversight of internal controls", "expertise in compliance and cybersecurity"] | ["Audit Committee"] | 2026 | ||
| GIOVANNA KAMPOURI MONNAS | Independent Director | 70 | ["Advisor to family and venture capital firms", "Director of Puig S.L.", "Chair of Exea Ventures", "Member of the Supervisory Board and Chair of the Compensation Committee of Randstad Holding NV", "Director at Imerys S.A.", "Executive at The Procter & Gamble Company", "President of Benckiser International"] | ["Management Development and Compensation"] | 2026 |
| ISABEL MAREY-SEMPER | Independent Director | 58 | ["President of DOXANANO", "Senior advisor to Jolt Capital", "Member of the Executive Committee of L\u2019Or\u00e9al S.A.", "Vice President and Head, Advanced Research at L\u2019Or\u00e9al", "Executive positions at Compagnie de Saint-Gobain S.A. and Stellantis N.V.", "Director of Rexel", "Key contributor to France 2030", "PhD in neuropharmacology from Sorbonne Universit\u00e9", "Masters in Business Administration"] | ["Corporate Governance"] | 2026 |
| JULIE XING | Executive Chair of Board of Mundipharma China; Independent Director | 57 | ["Senior healthcare executive with over 20 years of global experience across pharmaceuticals, medtech, digital health, biotech and diagnostics", "Executive Chair of the Board of Directors of Mundipharma China since 2022", "Global Senior Vice President, President of Greater China for Envista Holdings Corporation from 2019 to 2022", "Numerous leadership roles at Eli Lilly and Company", "Vice President and General Manager of Asia-Pacific and Japan Operations at Panomics and Affymetrix", "General Manager and China President of Illumina", "Operating Advisor focused on healthcare at Abu Dhabi Investment Authority since January 2026", "Board advisor of Lee Kum Kee Group since February 2025", "Board advisor to the Board of Directors of Mars, Incorporated from 2019 to 2024", "PhD in biology from the Hong Kong University of Science and Technology"] | ["Management Development and Compensation"] | 2026 |
| MATT TREROTOLA | Independent Director | 58 | ["Executive Advisor to CD&R and Enovis Corporation", "Chief Executive Officer at Enovis", "President and Chief Executive Officer of its predecessor Colfax Corporation", "Chair of the board of directors of Enovis", "Executive Vice President and member of the Office of the Chief Executive at DuPont de Nemours, Inc.", "responsible for DuPont\u2019s Electronics & Communications and Safety & Protection segments", "corporate responsibility for DuPont\u2019s Asia-Pacific business", "leadership roles at Danaher Corporation"] | ["Corporate Governance (Chair)"] | 2026 |
| RALF K. WUNDERLICH | Director | 59 | ["President and CEO of Huhtamaki Oyj", "Independent consultant", "Senior advisor to private equity firms", "Chair of the Board of Directors of Shepherd Building Group Ltd.", "Former director of Huhtamaki Oyj", "Former director of Essentra PLC", "Former director of Nordmeccanica S.p.A.", "Former director of Kl\u00f6ckner Pentaplast", "Former member of Amcor Limited\u2019s Global Executive Team", "Former President of Amcor Flexibles Asia Pacific", "Former director of LINPAC Group", "Former director of AMVIG Group", "Knowledge of and background in the packaging industry", "International experience in Europe, America, and Asia"] | ["Management Development and Compensation"] | 2026 |
| SARAH GLICKMAN | Independent Director | 56 | ["over 30 years of global financial and operational experience", "Chief Financial Officer and Principal Accounting Officer of Criteo S.A.", "Acting Chief Financial Officer at XPO, Inc.", "Senior Vice President, Corporate Finance and Transformation at XPO", "global executive roles at Novartis, Honeywell International and Bristol-Myers Squibb", "started career at PricewaterhouseCoopers", "served on the Board of Directors and was Chair of the Audit Committee for 2seventy bio, Inc.", "expertise in public company finance, accounting, strategic planning and risk management", "audit committee financial expert"] | ["Audit"] | 2026 |
| S. Glickman | ["audit committee financial expert", "experience in financial reporting", "oversight of internal controls", "expertise in compliance and cybersecurity"] | ["Audit Committee"] | 2026 | ||
| STEPHAN B. TANDA | President and Chief Executive Officer | 60 | ["President and Chief Executive Officer of Aptar since February 2017", "Executive Managing Board Director at Royal DSM NV from 2007 to 2017", "Director and Chair of the Nomination/Governance Committee of Ingredion Incorporated", "Director of Patheon NV"] | [] | 2026 |
